ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD.

Zhejiang Hisoar Pharmaceutical Co., Ltd.

002099

CNE000001PY2

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 09/05/2024 BST			5-day change	1st Jan Change
6.34 ^CNY	-1.25%		0.00%	-11.82%

04-28	Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-18	Hisoar Pharma's Unit Passes German Health Regulator's Inspection	MT

Tranche Update on Zhejiang Hisoar Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.

April 01, 2024 at 05:00 pm

From February 2, 2024 to March 31, 2024, the company has repurchased 21,874,798 shares, representing 1.35% for CNY 97.38 million. With this, the company has completed the repurchase of 21,874,798 shares, representing 1.35% for CNY 97.38 million under the buyback announced on February 3, 2024.

Latest news about Zhejiang Hisoar Pharmaceutical Co., Ltd.

Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-28	CI
Hisoar Pharma's Unit Passes German Health Regulator's Inspection	04-18	MT
Tranche Update on Zhejiang Hisoar Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.	04-01	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 300 million worth of its shares.	02-02	CI
Hisoar Pharma Chairman Plans Up to 20 Million Yuan Investment	02-02	MT
Zhejiang Hisoar Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	02-01	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23	CI
Zhejiang Hisoar Pharma Passes Good Manufacturing Practice Compliance Inspection	22/09/23	MT
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23	CI
Zhejiang Hisoar Pharma Registers New Drug For Diabetes Patients	11/07/23	MT
Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 24 May 2023	19/05/23	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Approves the Profit Distribution Proposal for 2022	16/05/23	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces the Profit Distribution Proposal for 2022	25/04/23	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	24/04/23	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/04/23	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Elects Tao Hong as Non-Independent Director; and Yu Yongping, Qian Jianmin and Liang Chao as Independent Directors	01/12/22	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	30/10/22	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22/08/22	CI
Hainan Visum Pharmaceutical Co Ltd announced that it has received $15 million in funding from Zhejiang Hisoar Pharmaceutical Co., Ltd.	28/06/22	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 25 May 2022	18/05/22	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Approves Dividend for 2021	16/05/22	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2021	25/04/22	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	25/04/22	CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	29/03/22	CI
Jiangxi Bilin Industrial Co., Ltd. announced that it expects to receive CNY 20 million in funding from Zhejiang Hisoar Pharmaceutical Co., Ltd.	27/01/22	CI

Chart Zhejiang Hisoar Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhejiang Hisoar Pharmaceutical Co., Ltd.

More charts

Company Profile

ZHEJIANG HISOAR PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the manufacture and sale of pharmaceutical materials and dyes. The Company operates through two segments: Pharmaceutical segment and Dye segment. Pharmaceutical segment manufactures and sells Active Pharmaceutical Ingredients (APIs) and preparations, as well as provides customized production and supporting research and development services for international pharmaceutical companies. The Companyâs pharmaceutical products comprise antibiotic series, hypoglycemic series and cardiovascular series. Dye segment is mainly involved in the manufacture and sale of environmentally friendly reactive dyes, dye intermediates and pigment intermediates. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

20/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD.	-11.82%	1.4B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals

Zhejiang Hisoar Pharmaceutical Co., Ltd.

Equities

002099

CNE000001PY2

Pharmaceuticals

Tranche Update on Zhejiang Hisoar Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.

Latest news about Zhejiang Hisoar Pharmaceutical Co., Ltd.

Chart Zhejiang Hisoar Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals